We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

122 hedge funds and large institutions have $1.2B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

370% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 10

158% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 19

130% more capital invested

Capital invested by funds: $522M → $1.2B (+$680M)

44% more funds holding

Funds holding: 85 → 122 (+37)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

39% less call options, than puts

Call options by funds: $5.44M | Put options by funds: $8.87M

Holders
122
Holders Change
+37
Holders Change %
+43.53%
% of All Funds
2.68%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
47
Increased
49
Reduced
19
Closed
10
Calls
$5.44M
Puts
$8.87M
Net Calls
-$3.42M
Net Calls Change
+$16.3M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$75.7M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$39M
3
Millennium Management
Millennium Management
New York
+$36.5M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$36M
5
Franklin Resources
Franklin Resources
California
+$24M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$34.3M
2
NLVP
New Leaf Venture Partners
New York
-$30.5M
3
EA
Emerald Advisers
Pennsylvania
-$11.6M
4
SHI
SV Health Investors
Massachusetts
-$11.1M
5
EP
Eversept Partners
New York
-$8.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$10.7M +$3.31M +111,827 +55%
PC
27
Polar Capital
United Kingdom
$10.4M +$9.06M +305,978 New
N
28
Nuveen
North Carolina
$10.3M +$7.48M +252,553 +508%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$9.64M +$1.99M +67,155 +31%
Capital World Investors
30
Capital World Investors
California
$9.16M +$7.99M +270,000 New
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$8.99M +$592K +20,000 +8%
RSCM
32
Rock Springs Capital Management
Maryland
$8.48M +$7.4M +250,000 New
Northern Trust
33
Northern Trust
Illinois
$8.37M +$3.67M +123,979 +101%
Deutsche Bank
34
Deutsche Bank
Germany
$7.88M +$3.96M +133,749 +136%
OM
35
Opaleye Management
Massachusetts
$7.81M -$2.37M -80,000 -26%
UBS AM
36
UBS AM
Illinois
$7.7M +$6.72M +226,999 New
KCM
37
Kornitzer Capital Management
Kansas
$7.08M -$118K -3,995 -2%
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$5.53M +$705K +23,802 +17%
Fidelity Investments
39
Fidelity Investments
Massachusetts
$5.18M +$2.91M +98,222 +181%
Goldman Sachs
40
Goldman Sachs
New York
$5.03M +$3.38M +114,306 +337%
Renaissance Technologies
41
Renaissance Technologies
New York
$4.88M +$4.25M +143,700 New
Charles Schwab
42
Charles Schwab
California
$3.69M +$659K +22,266 +26%
CC
43
Casdin Capital
New York
$3.39M +$2.96M +100,000 New
AA
44
ALPS Advisors
Colorado
$3.32M +$529K +17,884 +22%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$3.28M +$1.13M +38,224 +65%
SA
46
Sunesis Advisors
Kansas
$3.27M – – –
CIBC Asset Management
47
CIBC Asset Management
Ontario, Canada
$2.66M -$378K -12,771 -14%
FI
48
Fosun International
China
$2.34M -$1.75M -58,980 -46%
UBS Group
49
UBS Group
Switzerland
$1.93M +$1.37M +46,172 +429%
MAP
50
Moody Aldrich Partners
Massachusetts
$1.75M +$1.52M +51,451 New
1
2
3 4 5

DCPH Hedge Fund Activity: Q3 2019 in Review

122 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2019, worth a combined $1.2B — up 130% from $522M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new DCPH positions and 10 closed out — a net gain of 37 holders — while 49 added to existing stakes and 19 trimmed.

The largest buyer was Redmile Group, adding an estimated $75.7M. The largest seller was OrbiMed, cutting an estimated $34.3M.

  • 122 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2019, up from 85 in Q2 2019.
  • Funds reported $1.2B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 130% quarter-over-quarter.
  • 47 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 10 closed out, a net change of +37 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Redmile Group, an estimated $75.7M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was OrbiMed, an estimated $34.3M sold.

Based on aggregated 13F filings for Q3 2019.